NKp30/NCR3 Antibody (210845) [mFluor Violet 450 SE]
Novus Biologicals, part of Bio-Techne | Catalog # FAB1849MFV450
Clone 210845 was used by HLDA to establish CD designation
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Agonist Activity, CyTOF-ready, Flow Cytometry
Label
mFluor Violet 450 SE (Excitation = 406 nm, Emission = 445 nm)
Antibody Source
Monoclonal Mouse IgG2A Clone # 210845
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse T cell hybridoma transfected with human NKp30/NCR3 and Mouse myeloma cell line NS0-derived recombinant human NKp30 Fc Chimera
Specificity
Detects human NKp30/NCR3 on cell transfectants and peripheral blood NK cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for NKp30/NCR3 Antibody (210845) [mFluor Violet 450 SE]
Application
Recommended Usage
Agonist Activity
Optimal dilutions of this antibody should be experimentally determined.
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
0
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: NKp30/NCR3
Given its role in NK cell-mediated killing and activation, NKp30 is a potential target for cancer immunotherapies (6). For instance, Bi-specific T cell engagers (BiTE) is one immunotherapy approach targeting the NKp30/B7-H6 interaction where B7-H6-specific BiTE elicits an attack on tumor cells through interferon gamma (IFNgamma) production and T cell cytotoxicity (1). Another potential approach is NKp30-derived chimeric antigen receptors (CARs) where CAR-T cells that express chimeric NKp30 receptors can efficiently attack B7-H6 tumor cells (1,6).
References
1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The natural cytotoxicity receptors in health and disease. Frontiers in Immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909
2. Uniprot (O14931)
3. Luczo, J. M., Ronzulli, S. L., & Tompkins, S. M. (2021). Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30. Viruses, 13(2), 156. https://doi.org/10.3390/v13020156
4. Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., & Campbell, K. S. (2017). Regulation of the Functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression. Frontiers in Immunology, 8, 369.
5. Kaifu, T., Escaliere, B., Gastinel, L. N., Vivier, E., & Baratin, M. (2011). B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and Molecular Life Sciences : CMLS, 68(21), 3531-3539. https://doi.org/10.1007/s00018-011-0802-7
6. Pinheiro, P. F., Justino, G. C., & Marques, M. M. (2020). NKp30 - A prospective target for new cancer immunotherapy strategies. British Journal of Pharmacology, 177(20), 4563-4580. https://doi.org/10.1111/bph.15222
Alternate Names
CD337, NCR3
Gene Symbol
NCR3
Additional NKp30/NCR3 Products
Product Documents for NKp30/NCR3 Antibody (210845) [mFluor Violet 450 SE]
Product Specific Notices for NKp30/NCR3 Antibody (210845) [mFluor Violet 450 SE]
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...